UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Noninvasive O6 Methylguanine-DNA Methyltransferase Status Prediction in Glioblastoma Multiforme Cancer Using Magnetic Resonance Imaging Radiomics Features: Univariate and Multivariate Radiogenomics Analysis

World neurosurgery, 2019-12, Vol.132, p.e140-e161

2019

Volltextzugriff (PDF)

Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance

Biochimica et biophysica acta. Reviews on cancer, 2021-12, Vol.1876 (2), p.188616-188616, Article 188616

2021

Volltextzugriff (PDF)

TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway

Oncogene, 2015-01, Vol.34 (5), p.600-610

2015

Volltextzugriff (PDF)

Ubiquitin-conjugating enzyme E2 B regulates the ubiquitination of O-methylguanine-DNA methyltransferase and BCNU sensitivity in human nasopharyngeal carcinoma cells

Biochemical pharmacology, 2018-12, Vol.158, p.327-338

2018

Volltextzugriff (PDF)

AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage

Life sciences (1973), 2024-10, p.123111, Article 123111

2024

Volltextzugriff (PDF)

Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors

Biochimica et biophysica acta. Reviews on cancer, 2024-11, Vol.1879 (6), p.189184, Article 189184

2024

Volltextzugriff (PDF)

Ubiquitin-conjugating enzyme E2 B regulates the ubiquitination of O6-methylguanine-DNA methyltransferase and BCNU sensitivity in human nasopharyngeal carcinoma cells

Biochemical pharmacology, 2018-12, Vol.158, p.327-338

2018

Volltextzugriff (PDF)

How did lomustine become standard of care in recurrent glioblastoma?

Cancer treatment reviews, 2020-07, Vol.87, p.102029-102029, Article 102029

2020

Volltextzugriff (PDF)

MGMT et sensibilité au temozolomide

Bulletin du cancer, 2021-12, Vol.108 (12), p.1075-1076

Tabouret, Emeline

2021

Volltextzugriff (PDF)

Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma

Neuro-oncology (Charlottesville, Va.), 2018-05, Vol.20 (6), p.848-857

2018

Volltextzugriff (PDF)

MGMT Status as a Clinical Biomarker in Glioblastoma

Trends in Cancer, 2020-05, Vol.6 (5), p.380-391

2020

Volltextzugriff (PDF)

Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02

Clinical oncology (Royal College of Radiologists (Great Britain)), 2023-02, Vol.35 (2), p.e143-e152

2023

Volltextzugriff (PDF)

Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide

Neuro-oncology (Charlottesville, Va.), 2010-09, Vol.12 (9), p.917-927

2010

Volltextzugriff (PDF)

Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance

Expert opinion on drug delivery, 2022-11, Vol.19 (11), p.1397-1415

2022

Volltextzugriff (PDF)

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities

Frontiers in oncology, 2019-02, Vol.9, p.41-41

2019

Volltextzugriff (PDF)

Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone

Oncotarget, 2019-01, Vol.10 (6), p.660-672

2019

Volltextzugriff (PDF)

NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition

International journal of molecular sciences, 2021-05, Vol.22 (11), p.5907

2021

Volltextzugriff (PDF)

Immunohistochemistry for O6-methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: Correlation with promoter methylation status and patients’ progression-free survival with the cut-off value determined by ROC analysis

Journal of clinical neuroscience, 2020-03, Vol.73, p.231-236

2020

Volltextzugriff (PDF)

Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study

CNS oncology, 2021-09, Vol.10 (3)

2021

Volltextzugriff (PDF)

Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma

Biomaterials, 2022-08, Vol.287, p.121608, Article 121608

2022

Volltextzugriff (PDF)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (11), p.1935-1949

2022

Volltextzugriff (PDF)

Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice

Cancer, 2015-10, Vol.121 (19), p.3428-3434

2015

Volltextzugriff (PDF)

Imaging Findings of New Entities and Patterns in Brain Tumor

The Radiologic clinics of North America, 2021-05, Vol.59 (3), p.305-322

2021

Volltextzugriff (PDF)

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas

Pituitary, 2017-12, Vol.20 (6), p.643-653

2017

Volltextzugriff (PDF)

1 – 25 von 1.758

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.558)
Mit Volltextzugriff
(1.564)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.348)
Life Sciences & Biomedicine
(1.306)
Mgmt
(1.199)
Humans
(1.016)
Oncology
(733)
Dna Methylation
(614)
Glioblastoma
(587)
Male
(510)
Female
(509)
Temozolomide
(486)
Dna Repair Enzymes - Genetics
(466)
Dna Modification Methylases - Genetics
(463)
Tumor Suppressor Proteins - Genetics
(459)
Middle Aged
(455)
Adult
(392)
Aged
(375)
Neurosciences & Neurology
(374)
Tumors
(368)
Prognosis
(343)
Brain Neoplasms - Genetics
(340)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Neuro-Oncology
(101)
Neuro-Oncology
(50)
Cancers
(32)
International Journal Of Molecular Sciences
(32)
Frontiers In Oncology
(29)
International Journal Of Cancer
(29)
Oncotarget
(29)
Carcinogenesis
(21)
Anticancer Research
(19)
Acta Neuropathologica
(18)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Noninvasive O6 Methylguanine-DNA Methyltransferase Status Prediction in Glioblastoma Multiforme Cancer Using Magnetic Resonance Imaging Radiomics Features: Univariate and Multivariate Radiogenomics Analysis

Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance

TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway

Ubiquitin-conjugating enzyme E2 B regulates the ubiquitination of O-methylguanine-DNA methyltransferase and BCNU sensitivity in human nasopharyngeal carcinoma cells

AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage

Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors

Ubiquitin-conjugating enzyme E2 B regulates the ubiquitination of O6-methylguanine-DNA methyltransferase and BCNU sensitivity in human nasopharyngeal carcinoma cells

How did lomustine become standard of care in recurrent glioblastoma?

MGMT et sensibilité au temozolomide

Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma

MGMT Status as a Clinical Biomarker in Glioblastoma

Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02

Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide

Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities

Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone

NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition

Immunohistochemistry for O6-methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: Correlation with promoter methylation status and patients’ progression-free survival with the cut-off value determined by ROC analysis

Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study

Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice

Imaging Findings of New Entities and Patterns in Brain Tumor

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

Suchergebnisse filtern